


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT
AZITHROMYCIN FOR SUSPENSION AND
FLUCONAZOLE AND SODIUM CHLORIDE INJECTION
OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Azithromycin for Suspension (strength: 0.1g), an anti bacterial infection drug developed by the Group’s subsidiary Jilin Sihuan Pharmaceutical Co., Ltd. (“**Jilin Sihuan Pharmaceutical**”), and the anti fungal infection drug Fluconazole and Sodium Chloride Injection (strength: 100ml: 0.2g fluconazole and 0.9g sodium chloride; 50ml: 0.1g fluconazole and 0.45g sodium chloride) developed by the Group’s subsidiary Honghe Pharmaceutical Co., Ltd. (“**Honghe Pharmaceutical**”), have obtained drug registration approval from the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (“**China**”), and both are deemed to have passed the consistency evaluation on quality and efficacy of generic drugs.

About Azithromycin for Suspension

Azithromycin is a new generation (second generation) macrolide antibiotic used for infections caused by allergic bacteria, such as Bronchitis, pneumonia, pharyngitis and other upper and lower respiratory tract infections; skin and soft tissue infections. The current clinical use of Azithromycin is mainly administered as an oral solid dosage or intravenous injection, which causes great inconvenience to infants and children. Compared with other dosage forms, the dry suspension form has fast absorption, high bioavailability and longer duration of efficacy, making it a commonly used antibiotic in children. It is a commonly used antibiotic in children. In addition, Azithromycin or Suspension has a high patient compliance rate (easy to administer, aromatic and well tolerated) and is the most commonly used antibiotic in children. It is recommended by guidelines and expert consensus.

The Azithromycin for Suspension of is a Category B drug under the National Reimbursement Drug List. According to public data, in 2021, the dry suspension of Azithromycin's sales growth rate in public healthcare market exceeded 90%, and in retail channels was nearly 40%.

About Fluconazole and Sodium Chloride Injection

Fluconazole is a pyrrole antifungal drug used for the treatment of fungal infections such as cryptococcosis, coccidioidomycosis and candidiasis. Fluconazole and Sodium Chloride Injection is a Class B drug under the National Reimbursement Drug List and is a national essential drug.

According to IQVIA data, the sales scale of Fluconazole and Sodium Chloride Injection in 2021 is approximately RMB640 million. Currently, with the relaxation of the epidemic prevention and control policy, the market sales of anti-infective drugs will continue to increase.

The area of anti-infection is a key area of focus for the Group. The Azithromycin for Suspension of (specification: 0.1 g) and Fluconazole and Sodium Chloride Injection (Specifications: 100ml: Fluconazole 0.2g and Sodium Chloride 0.9g; 50ml: Fluconazole 0.1g and Sodium Chloride 0.45g) have been granted a drug registration approval, which will further benefit a wide range of patients. It also adds another important product to the Group's anti-infective drug pipeline, which will facilitate future sales and market competition for this product and have a positive impact on the Group's operating results.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 6 June 2023

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.